Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.

UNLABELLED Constitutive activation of NF-κB is a hallmark of the activated B cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), owing to upstream signals from the B-cell receptor (BCR) and MYD88 pathways. The linear polyubiquitin chain assembly complex (LUBAC) attaches linear polyubiquitin chains to IκB kinase-γ, a necessary event in some pathways that engage NF-κB. Two germline polymorphisms affecting the LUBAC subunit RNF31 are rare among healthy individuals (∼1%) but enriched in ABC DLBCL (7.8%). These polymorphisms alter RNF31 α-helices that mediate binding to the LUBAC subunit RBCK1, thereby increasing RNF31-RBCK1 association, LUBAC enzymatic activity, and NF-κB engagement. In the BCR pathway, LUBAC associates with the CARD11-MALT1-BCL10 adapter complex and is required for ABC DLBCL viability. A stapled RNF31 α-helical peptide based on the ABC DLBCL-associated Q622L polymorphism inhibited RNF31-RBCK1 binding, decreased NF-κB activation, and killed ABC DLBCL cells, credentialing this protein-protein interface as a therapeutic target. SIGNIFICANCE We provide genetic, biochemical, and functional evidence that the LUBAC ubiquitin ligase is a therapeutic target in ABC DLBCL, the DLBCL subtype that is most refractory to current therapy. More generally, our findings highlight the role of rare germline-encoded protein variants in cancer pathogenesis.

[1]  Keiji Tanaka,et al.  Defective immune responses in mice lacking LUBAC‐mediated linear ubiquitination in B cells , 2013, The EMBO journal.

[2]  G. Lenz,et al.  The protease activity of the paracaspase MALT1 is controlled by monoubiquitination , 2013, Nature Immunology.

[3]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[4]  V. Pascual,et al.  Immunodeficiency, auto-inflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency , 2012, Nature Immunology.

[5]  I. Dikic,et al.  A20 inhibits LUBAC‐mediated NF‐κB activation by binding linear polyubiquitin chains via its zinc finger 7 , 2012, The EMBO journal.

[6]  H. Nishimasu,et al.  Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF‐κB regulation , 2012, The EMBO journal.

[7]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[8]  T. Sixma,et al.  The E3 ligase HOIP specifies linear ubiquitin chain assembly through its RING-IBR-RING domain and the unique LDD extension , 2012, The EMBO journal.

[9]  K. Rittinger,et al.  LUBAC synthesizes linear ubiquitin chains via a thioester intermediate , 2012, EMBO reports.

[10]  Jacob A. Tennessen,et al.  Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes , 2012, Science.

[11]  Paul Shinn,et al.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.

[12]  T. Mizushima,et al.  A non‐canonical UBA–UBL interaction forms the linear‐ubiquitin‐chain assembly complex , 2012, EMBO reports.

[13]  L. Staudt,et al.  Pathogenesis of human B cell lymphomas. , 2012, Annual review of immunology.

[14]  S. Miyamoto,et al.  DNA damage‐dependent NF‐κB activation: NEMO turns nuclear signaling inside out , 2012, Immunological reviews.

[15]  Zhijian J. Chen,et al.  Ubiquitination in signaling to and activation of IKK , 2012, Immunological reviews.

[16]  K. Brown,et al.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.

[17]  S. Puig,et al.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.

[18]  K. Iwai,et al.  LUBAC regulates NF‐κB activation upon genotoxic stress by promoting linear ubiquitination of NEMO , 2011, The EMBO journal.

[19]  J. Colgan,et al.  HOIL-1L Interacting Protein (HOIP) Is Essential for CD40 Signaling , 2011, PloS one.

[20]  Daniel E. Zak,et al.  Systems analysis identifies an essential role for SHANK-associated RH domain-interacting protein (SHARPIN) in macrophage Toll-like receptor 2 (TLR2) responses , 2011, Proceedings of the National Academy of Sciences.

[21]  A. Marshak‐Rothstein,et al.  Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. , 2011, Seminars in immunology.

[22]  B. Maček,et al.  SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis , 2011, Nature.

[23]  Y. Saeki,et al.  SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex , 2011, Nature.

[24]  Anthony W. Purcell,et al.  Linear ubiquitination prevents inflammation and regulates immune signalling , 2011, Nature.

[25]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[26]  C. Wilkerson,et al.  HOIL-1L Interacting Protein (HOIP) as an NF-κB Regulating Component of the CD40 Signaling Complex , 2010, PloS one.

[27]  Jan Delabie,et al.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.

[28]  Christoph H Emmerich,et al.  Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. , 2009, Molecular cell.

[29]  L. Staudt,et al.  Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma , 2009, Proceedings of the National Academy of Sciences.

[30]  J. Ruland,et al.  Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells , 2009, The Journal of experimental medicine.

[31]  S. Akira,et al.  Involvement of linear polyubiquitylation of NEMO in NF-κB activation , 2009, Nature Cell Biology.

[32]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[33]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[34]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[35]  L. Staudt,et al.  Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. , 2008, Blood.

[36]  Jan Delabie,et al.  Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.

[37]  Seda Çöl Arslan,et al.  Malt1 ubiquitination triggers NF‐κB signaling upon T‐cell activation , 2007 .

[38]  S. Korsmeyer,et al.  Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. , 2007, Journal of the American Chemical Society.

[39]  Taku Sato,et al.  Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors. , 2006, Leukemia research.

[40]  Liming Yang,et al.  A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.

[41]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[42]  Zhijian J. Chen,et al.  The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. , 2004, Molecular cell.

[43]  H. Ohno,et al.  Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B‐cell lymphoma , 2003, Cancer science.

[44]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[45]  A. Baldwin.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. , 2001, The Journal of clinical investigation.

[46]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[47]  J. Thornton,et al.  Helix geometry in proteins. , 1988, Journal of molecular biology.

[48]  M. Abe,et al.  Characterization and comparison of two newly established epstein‐barr virus‐negative lymphoma B‐cell lines: Surface markers, growth characteristics, cytogenetics, and transplantability , 1988, Cancer.

[49]  M. Minden,et al.  The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. , 1987, Blood.

[50]  Seda Çöl Arslan,et al.  Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. , 2007, The EMBO journal.

[51]  L. Staudt,et al.  Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  L. Staudt,et al.  Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .

[53]  Zhijian J. Chen,et al.  The TRAF 6 Ubiquitin Ligase and TAK 1 Kinase Mediate IKK Activation by BCL 10 and MALT 1 in T Lymphocytes , 2022 .